volume 24, issue 2, P257-272 2010
DOI: 10.1016/j.idc.2010.01.010
View full text
|
|
Share
John R. Wingard, Jack Hsu, John W. Hiemenz

Abstract: Hematopoietic stem cell transplantation (HSCT) is a treatment for multiple medical conditions that result in bone marrow failure and as an antineoplastic adoptive immunotherapy for hematologic malignancies. HSCT is associated with profound compromises in host barriers and all arms of innate and acquired immunity. The degree of immune compromise varies by type of transplant and over time. Immune reconstitution occurs within several months after autologous HSCT but takes up to a year or longer after allogeneic H…

expand abstract